High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit

doi:10.1128/AAC.00813-10

. 2011 Jan;55(1):433-5.

doi: 10.1128/AAC.00813-10. Epub 2010 Oct 11.

High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit

Carole Giraud¹, Sandra Manceau, Mehdi Oualha, Hélène Chappuy, Agnès Mogenet, Patrick Duchêne, Sarah Ducrocq, Philippe Hubert, Jean M Treluyer

Affiliations

PMID: 20937783
PMCID: PMC3019675
DOI: 10.1128/AAC.00813-10

High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit

Carole Giraud et al. Antimicrob Agents Chemother. 2011 Jan.

. 2011 Jan;55(1):433-5.

doi: 10.1128/AAC.00813-10. Epub 2010 Oct 11.

Authors

Carole Giraud¹, Sandra Manceau, Mehdi Oualha, Hélène Chappuy, Agnès Mogenet, Patrick Duchêne, Sarah Ducrocq, Philippe Hubert, Jean M Treluyer

Affiliation

¹ Groupe Hospitalier Broca/Cochin/Hôtel Dieu, Assistance Publique Hôpitaux de Paris, Unité de Recherche Clinique, Paris, France. carole.giraud@cch.aphp.fr

PMID: 20937783
PMCID: PMC3019675
DOI: 10.1128/AAC.00813-10

Abstract

During the 2009 H1N1 influenza pandemics, the concentrations of oseltamivir (O) and its active metabolite (oseltamivir carboxylate [OC]) were determined in 11 children (1 month to 16 years of age) admitted to intensive care units for presumed severe H1N1 infection. They received oseltamivir phosphate (OP) nasogastrically at doses between 1.5 and 6.8 mg/kg of body weight. High OC concentrations were found, with a mean level of 678 ± 535 μg/liter. The mean OP concentration was 27 ± 52 μg/liter. No marked side effect was reported.

PubMed Disclaimer

Cited by

Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children.
Tang Girdwood SC, Mizuno T, Krallman KA, Benken LA, Stoneman EM, Yunger TM, Wong HR, Vinks AA, Kaplan JM. Tang Girdwood SC, et al. Pediatr Infect Dis J. 2019 Dec;38(12):1224-1227. doi: 10.1097/INF.0000000000002473. Pediatr Infect Dis J. 2019. PMID: 31738337 Free PMC article.
Influenza virus-related critical illness: prevention, diagnosis, treatment.
Chow EJ, Doyle JD, Uyeki TM. Chow EJ, et al. Crit Care. 2019 Jun 12;23(1):214. doi: 10.1186/s13054-019-2491-9. Crit Care. 2019. PMID: 31189475 Free PMC article. Review.
Influenza and the use of oseltamivir in children.
Çiftçi E, Karbuz A, Kendirli T. Çiftçi E, et al. Turk Pediatri Ars. 2016 Jun 1;51(2):63-71. doi: 10.5152/TurkPediatriArs.2016.2359. eCollection 2016 Jun. Turk Pediatri Ars. 2016. PMID: 27489462 Free PMC article. Review.

References

1. Abe, M., J. Smith, A. Urae, J. Barrett, H. Kinoshita, and C. R. Rayner. 2006. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann. Pharmacother. 40:1724-1730. - PubMed
1. Acosta, E. P., P. Jester, P. Gal, J. Wimmer, J. Wade, R. J. Whitley, and D. W. Kimberlin. 2010. Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis. 202:563-566. - PMC - PubMed
1. Ariano, R. E., D. S. Sitar, S. A. Zelenitsky, R. Zarychanski, A. Pisipati, S. Ahern, S. Kanji, J. Rello, and A. Kumar. 2010. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 182:357-363. - PMC - PubMed
1. Bantia, S., C. D. Parker, S. L. Ananth, L. L. Horn, K. Andries, P. Chand, P. L. Kotian, A. Dehghani, Y. El-Kattan, T. Lin, T. L. Hutchison, J. A. Montgomery, D. L. Kellog, and Y. S. Babu. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167. - PMC - PubMed
1. Brewster, M., J. R. Smith, R. Dutkowski, and R. Robson. 2006. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. Vaccine 24:6660-6663. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Abe, M., J. Smith, A. Urae, J. Barrett, H. Kinoshita, and C. R. Rayner. 2006. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann. Pharmacother. 40:1724-1730. - PubMed

[2] Abe, M., J. Smith, A. Urae, J. Barrett, H. Kinoshita, and C. R. Rayner. 2006. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann. Pharmacother. 40:1724-1730. - PubMed

[3] Acosta, E. P., P. Jester, P. Gal, J. Wimmer, J. Wade, R. J. Whitley, and D. W. Kimberlin. 2010. Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis. 202:563-566. - PMC - PubMed

[4] Acosta, E. P., P. Jester, P. Gal, J. Wimmer, J. Wade, R. J. Whitley, and D. W. Kimberlin. 2010. Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis. 202:563-566. - PMC - PubMed

[5] Ariano, R. E., D. S. Sitar, S. A. Zelenitsky, R. Zarychanski, A. Pisipati, S. Ahern, S. Kanji, J. Rello, and A. Kumar. 2010. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 182:357-363. - PMC - PubMed

[6] Ariano, R. E., D. S. Sitar, S. A. Zelenitsky, R. Zarychanski, A. Pisipati, S. Ahern, S. Kanji, J. Rello, and A. Kumar. 2010. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 182:357-363. - PMC - PubMed

[7] Bantia, S., C. D. Parker, S. L. Ananth, L. L. Horn, K. Andries, P. Chand, P. L. Kotian, A. Dehghani, Y. El-Kattan, T. Lin, T. L. Hutchison, J. A. Montgomery, D. L. Kellog, and Y. S. Babu. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167. - PMC - PubMed

[8] Bantia, S., C. D. Parker, S. L. Ananth, L. L. Horn, K. Andries, P. Chand, P. L. Kotian, A. Dehghani, Y. El-Kattan, T. Lin, T. L. Hutchison, J. A. Montgomery, D. L. Kellog, and Y. S. Babu. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167. - PMC - PubMed

[9] Brewster, M., J. R. Smith, R. Dutkowski, and R. Robson. 2006. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. Vaccine 24:6660-6663. - PubMed

[10] Brewster, M., J. R. Smith, R. Dutkowski, and R. Robson. 2006. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. Vaccine 24:6660-6663. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit

Affiliation

High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Miscellaneous